In December 2024, the adult sons of Marjorie Tingley received an urgent email from the dementia care unit at Vista Grande Villa, a senior living community in Michigan. Administrators told them their 85-year-old mother had become a serious safety threat to staff and to herself. According to facility behavior logs, Tingley had struck, kicked, or elbowed aides on at least ten days that November, lashing out while they attempted to change her briefs, dress her, bathe her, or help her use the bathroom. Vista Grande requested permission to sedate her.
That request set off a bitter, months-long dispute between Tingley's sons and the facility over one of the most fraught issues in long-term care: the use of antipsychotic drugs to calm agitated residents with dementia. The medications carry serious risks. The Food and Drug Administration requires drugmakers to warn that these powerful compounds raise the likelihood of death in older adults living with Alzheimer's disease and similar conditions. Even so, they remain a common tool for managing behavior that staff find difficult to handle.
The scale of the problem is enormous. More than 5 million Medicare beneficiaries carry a dementia diagnosis. Despite a 14-year federal campaign aimed at reducing the use of psychotropic drugs in nursing homes and similar settings, roughly one in four Medicare beneficiaries with dementia are potentially inappropriately prescribed antipsychotics and other brain-altering medications. Those drugs can trigger delirium, contribute to falls, and lead to hospitalizations, according to a study published in JAMA.
For families, the decision is rarely simple. Agitation and aggression are common features of advanced dementia, and caregivers who are untrained or overwhelmed may have few alternatives when a resident becomes combative during routine care. Facilities argue that sedating medications are sometimes the only way to protect staff and other residents from injury. Families, meanwhile, worry that drugs are being used as a chemical restraint to make patients easier to manage rather than to treat a genuine medical need.
Tingley's sons fell firmly on the side of caution. They resisted Vista Grande's push to medicate their mother, setting up a clash that exposes how little guidance families and legal guardians receive when they must weigh a parent's immediate safety against the long-term hazards of sedation. The dispute also illustrates how much power facilities hold in these negotiations, since they control daily care and can frame a resident's behavior as an emergency requiring pharmacological intervention.
Federal regulators have tried for years to curb the practice. The centers that oversee nursing home quality have pushed facilities to document behavior carefully, try non-drug approaches first, and reserve antipsychotics for narrowly defined circumstances. Yet the JAMA findings suggest those efforts have not been enough. The persistent prescribing rates point to systemic pressures: thin staffing, limited access to behavioral specialists, and a reimbursement system that does not reward the labor-intensive work of calming a distressed resident without medication.
Advocates for residents argue that the drugs are too often a shortcut. Antipsychotics were developed to treat schizophrenia and bipolar disorder, not the disorientation and fear that accompany dementia. When given to older adults, they can cause sedation, confusion, tremors, and an elevated risk of stroke and death. Critics say facilities frequently turn to them when they lack the staff or training to respond to agitation with patience and environmental adjustments.
Vista Grande's behavior logs, cited in the dispute over Tingley's care, describe a pattern of physical outbursts during intimate care tasks. Such moments are among the hardest for dementia patients, who may not understand what is being done to them and may react with fear or resistance. Dementia care specialists say the solution is often to change how care is delivered, not to sedate the person receiving it. That can mean approaching residents more slowly, explaining each step, or assigning caregivers the resident already trusts.
Still, the pressure on facilities is real. Understaffed units sometimes have one aide responsible for a dozen or more residents, leaving little time for the slow, individualized attention that could prevent an outburst. When a resident injures a worker, the facility faces workers' compensation claims and regulatory scrutiny. In that environment, a prescription can look like the fastest path to calm.
Tingley's case also raises questions about who gets to decide. Adult children often serve as informal guardians, but their authority can be contested when a facility believes a resident is in danger. Families may not know they can request a second medical opinion, ask for a behavioral care plan, or seek help from a long-term care ombudsman. The result is that many give in to sedation simply because they lack the resources or stamina to fight.
The emotional toll on relatives is severe. Watching a parent with dementia become aggressive is painful in itself; being asked to authorize a drug that could shorten that parent's life adds another layer of anguish. Tingley's sons spent months pushing back, a decision that required them to challenge professionals who claimed to know their mother's needs better than they did.
Their struggle reflects a broader national question. As the population ages and dementia diagnoses rise, more families will confront the same choice. Policymakers, researchers, and care providers are still searching for a balance that protects residents and staff without resorting to medications that carry black-box warnings. Until that balance is found, disputes like the one at Vista Grande Villa will keep repeating in care units across the country.
(0)